Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: STTK

Shattuck Labs, Inc.

Healthcare | Biotechnology

Market prices for STTK are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Shattuck Labs, Inc. (NASDAQ: STTK) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:57 UTC.

What Shattuck Labs, Inc. does

The company is a clinical-stage biotechnology firm developing monoclonal and bispecific antibodies that block Death Receptor 3 (DR3) to treat inflammatory and immune-mediated diseases. Its lead program, SL-325, is a DR3 blocking antibody designed to inhibit the DR3/TL1A pathway more effectively than existing TL1A blocking antibodies. The company is currently running a Phase 1 trial of SL-325 in healthy volunteers and plans to begin a Phase 2 trial in Crohn's Disease patients.

Summarized from Shattuck Labs, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-59.24%

Revenue, margins & earnings

FY2021: net loss $45M on revenue $30M$30MFY2021FY2022: net loss $102M on revenue $652,000$652,000FY2022FY2023: net loss $87M on revenue $2M$2MFY2023FY2024: net loss $75M on revenue $6M$6MFY2024FY2025: net loss $49M on revenue $1M$1MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-07-07
Most recent filed transactions — July 2026:
  • 2026-07-07Chief Technical OfficerStock Option (Right to Buy)Option exercise-410—
  • 2026-07-07Chief Technical OfficerSale-410$2.9K
  • 2026-07-07Chief Technical OfficerStock Option (Right to Buy)Option exercise-12,153—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Shattuck Labs, Inc. do?

The company is a clinical-stage biotechnology firm developing monoclonal and bispecific antibodies that block Death Receptor 3 (DR3) to treat inflammatory and immune-mediated diseases.

When did STTK last file with the SEC?

Shattuck Labs, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-11. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:57 UTC. This page is also available as JSON at /api/data?ticker=STTK and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for STTK and 5,000+ tickers.

Create a free account — keep STTK
For your agent
GET /api/data?ticker=STTK

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt